The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Therapeutic Use
- 27 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
- 27 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
- 10 Jun 2017 Biomarkers information updated